Amgen Stock Dips as Weight-Loss Drug Faces Digestive Concerns
Amgen’s stock drops as its weight-loss drug faces scrutiny over severe digestive side effects. Despite early promise in the competitive obesity market, concerns about safety and delays loom. The company vows to address issues, while investors remain cautious about the drug’s future.